Natera, Inc. $NTRA Shares Purchased by Chevy Chase Trust Holdings LLC

Key Points

• Chevy Chase Trust Holdings LLC increased its stake in Natera, Inc. by 5.4% during Q2, now owning approximately 0.44% of the company worth around $100.8 million.
• Natera's most recent quarterly earnings reported a loss of ($0.74) per share, which was lower than analyst expectations, but its revenue increased by 32.2% year-over-year to $546.6 million.
• Analysts have a mostly positive outlook on Natera, with a majority rating it as a "Moderate Buy" and setting an average price target of $196.81.

Chevy Chase Trust Holdings LLC grew its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 5.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 596,939 shares of the medical research company's stock after acquiring an additional 30,390 shares during the period. Chevy Chase Trust Holdings LLC owned about 0.44% of Natera worth $100,847,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. HighPoint Advisor Group LLC lifted its position in shares of Natera by 30.8% during the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock valued at $308,000 after acquiring an additional 468 shares during the period. Park Avenue Securities LLC acquired a new stake in shares of Natera during the 2nd quarter valued at approximately $1,525,000. Amalgamated Bank lifted its position in shares of Natera by 9.8% during the 1st quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock valued at $1,173,000 after acquiring an additional 740 shares during the period. Comerica Bank lifted its position in shares of Natera by 24.1% during the 1st quarter. Comerica Bank now owns 141,106 shares of the medical research company's stock valued at $19,954,000 after acquiring an additional 27,379 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of Natera by 32.3% during the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock valued at $120,000 after acquiring an additional 207 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Up 0.6%

Shares of NASDAQ NTRA opened at $180.54 on Friday. Natera, Inc. has a 52-week low of $117.27 and a 52-week high of $187.34. The firm has a fifty day moving average of $167.60 and a 200-day moving average of $158.07. The stock has a market capitalization of $24.78 billion, a PE ratio of -94.52 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. During the same period in the prior year, the firm earned ($0.30) earnings per share. The firm's quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Equities research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on NTRA. Morgan Stanley reiterated an "overweight" rating and set a $195.00 price target on shares of Natera in a research report on Sunday, August 10th. Piper Sandler restated an "overweight" rating and set a $220.00 price objective (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Cowen restated a "buy" rating on shares of Natera in a research report on Friday, August 8th. Wells Fargo & Company assumed coverage on Natera in a research report on Monday, September 22nd. They set an "equal weight" rating and a $175.00 price objective for the company. Finally, Royal Bank Of Canada set a $268.00 price objective on Natera and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Natera has an average rating of "Moderate Buy" and an average price target of $196.81.

Insider Activity at Natera

In other news, insider John Fesko sold 678 shares of the business's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $155.46, for a total transaction of $105,401.88. Following the completion of the sale, the insider directly owned 152,747 shares of the company's stock, valued at $23,746,048.62. The trade was a 0.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven Leonard Chapman sold 14,083 shares of the business's stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $160.00, for a total transaction of $2,253,280.00. Following the sale, the chief executive officer directly owned 154,072 shares of the company's stock, valued at $24,651,520. This represents a 8.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 72,464 shares of company stock worth $10,963,125. 5.63% of the stock is owned by corporate insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.